Radiation ExposureNCT04403815
Radiation Exposure During Coronary Procedures According to Vascular Access
An observational study of Radiation Exposure, run by Azienda ULSS 3 Serenissima.
Trial summary
Trial's objective is to evaluate: i. if there's any difference between the operator radiation exposure during diagnostic coronary angiography and/or percutaneous coronary intervention (PCI) performed through right-side artery accesses (wrist transradial access and distal transradial access) versus left distal radial… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Radiation Exposure
- What is being tested?
- vascular access for coronary procedures
- Type of treatment
- Surgery or procedure
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2020to 1 Sep 2021
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: all-comers undergoing to diagnostic coronary angiography and/or PCI through transradial access
Who may be able to join
- patients admitted for coronary diagnostic angiography in the setting of valvular disease, stable angina, suspected coronary artery disease, acute coronary syndrome with or without ST segment elevation myocardial infarction who underwent diagnostic coronary angiography through right radial, right distal radial and left distal radial access.
- patients admitted for ad-Hoc PCI through any radial access
- patients age > 18 years-old
- signed informed consent
Who cannot join
- hemodynamic instability
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Determinants of Operator Radiation Exposure During Percutaneous Coronary Procedures According to Vascular Access: the RADIANT II Observational Study
Trial's objective is to evaluate:
- if there's any difference between the operator radiation exposure during diagnostic coronary angiography and/or percutaneous coronary intervention (PCI) performed through right-side artery accesses (wrist transradial access and distal transradial access) versus left distal radial artery access ii. the relationship between operator radiation exposure and other clinical and procedural characteristics, to assess independent predictors of operator radiation exposure. Design of the study: prospective multicenter observational cohort registry (OCR).
The purpose of this OCR is to assess the radiation exposure of interventional cardiologist during a diagnostic coronary angiography and/or PCI according to vascular access used (see above). Coronary angiography and PCI will be performed according to usual practice
Read the detailed description
Patient population:
During 6 months, at least 1000 consecutive patients (age > 18 years) referred for diagnostic coronary angiography in up to 10 centers in Italy involving a minimum of 4 operators will be enrolled. To be qualified as expert, operators should have performed at least 250 transradial procedure/year in the previous 3 years and have performed at least 20 right and left distal radial procedures.
Demographic and medical history data of patients including age, sex, history of diabetes mellitus, hypertension, height and weight will be collected. Height and weight of operators will be also recorded. Type of angiographic system will be recorded. Procedural data as contrast medium amount, subclavian tortuosity, numbers of diagnostic and guiding catheters and numbers of cine-angiographic acquisitions (frames) will be also recorded.
Subclavian tortuosity will be classified as:
- Grade 1: tortuosity or calcification of the subclavian artery that can be crossed by a standard 0.035" nonhydrophilic wire facilitated with deep inspiration
- Grade 2: tortuosity or calcification of the subclavian artery that can be crossed with a 0.0035" hydrophilic wire and a standard diagnostic catheter
- Grade 3: tortuosity or calcification of the subclavian artery or congenital anomalies that require a 0.035" stiff wire and a standard catheter
- Grade 4: severe tortuosity and/or calcification of the subclavian artery or congenital anomalies preventing the catheter or guide to reach the aortic valve plane or engage the coronary ostia with a stiff wire Subclavian tortuosity > grade 2 will be considered as significative. Type of catheters and the number of views for angiography and PCI will be left to the discretion of the operator. Lead shields placed under the catheterization table, as well as ceiling mounted lead shields, will be used in every procedure. Procedural success is defined as completion of the procedure through the intended arterial access. Crossover, if needed, is permitted to femoral access or to contralateral arm or approach.
Arterial access protocol:
Right radial access: radial artery access will be obtained with a 20-gauge Teflonsheated needle using the Seldinger or the counter puncture technique. An introducer sheath is inserted in the radial artery according to local practice. An intra-arterial vasodilator cocktail will be administered consisting of ntroglycerin 200 mcg and verapamil 5 mg after sheath insertion. 5000 IU of unfractioned heparin will be administered intravenously after sheath insertion, and adequately adjusted in case of interventions. The introducer sheath will be removed at the end of the procedure, and a mechanical or inflatable pressure band will be applied to the access site to achieve hemostasis.
Distal radial accesses: following distal radial artery palpation, 1 of the 2 possible puncture sites (anatomic snuffbox or in the first intermetacarpal space) is chosen. In case of left-side access, the left hand is bent toward the left groin with support below the left elbow to ensure patient's comfort. The operator is positioned at the right side of the patient. To favor a shift of the distal radial artery to the surface of the fossa, the patient is asked to grasp his or her thumb under the other 4 fingers or to hold a roll of gauze, a 20 ml syringe, or the handle of a dedicated system. After disinfection and local anesthesia, the artery is punctured according to operator preference and/or experience using a micropuncture needle or a cannula-over-needle. An introducer sheath (preferably a slender introducer sheath) is inserted in the radial artery according to local practice. An intra-arterial vasodilator cocktail will be administered consisting of nitroglycerin 200 mcg and verapamil 5 mg after sheath insertion. 5000 IU of unfractioned heparin will be administered intravenously after sheath insertion, and adequately adjusted in case of interventions.
Coronary catheterization:
Angiographic systems were set according to the standard of the operators, and the field of view or fluoroscopic and cine-acquisition speed will be recorded for each procedure. The diagnostic procedures will be performed using a standard sequence of 3 projections for the right coronary artery and maximum 6 projections for the left coronary artery. Differently, the percutaneous coronary interventions will be performed according to the lesion and to the operator preference.
Vascular access as well as the sheath selection, catheter curve used, and the use of adjunctive tools will be at the discretion of the operator involved in the procedure.
In all procedures, standard operator radioprotection will be ensured using a lead apron, a thyroid lead collar, lower body x-ray curtain fixed on the angiographic table, an upper mobile leaded glass suspended from the ceiling, and leaded glasses. The use of adjunctive protective drapes to reduce operator radiation exposition ws left to the operator's discretion
Radiation measurement:
Radiation measures collected are fluoroscopy time (expressed in minutes), the AK (expressed in mGy) and the DAP (expressed in Gy*cm2). The number of acquired cineangiograms will be recorded. Fluoroscopy and cineangiography will be performed at 7.5 or 15 frames/s according to operators' preferences.
Operator radiation exposure is measured for each participating operator using 1 dedicated electronic dosimeter (PM1610B; Polimaster, Vienna, Austria) to be worn at mid-thorax level, in the breast pocket outside the lead apron, and expressed in µSy. The radiation and operator measures will be recorded at the beginning and the end of each procedure. For those patients who undergo a PCI after the diagnostic procedure, the measures of fluoroscopy time, DAP, and dose of the wearable dosimeters will be reset after the end of the diagnostic procedure and restart at the beginning of the PCI. To take into account possible differences in patient radiation dose affecting the operator exposure, the DAP-normalized operator dose will be also calculated.
The equivalent dose at the thorax will be also converted in operator effective dose dividing it by a factor of 33 according to apron thickness, 0.5 lead equivalent with a tube voltage under the table. Patient effective dose will be calculated using a conversion factor of 0.20 mSv/Gy*cm2.
Statistical Hypothesis and analysis:
the null hypothesis is that ld-TRA exposure to radiation is the same as right-side TRA (access site at the wrist and at the anatomical snuffbox of the right hand). In the previous RADIANT study right-side TRA was associated with a mean operator exposition of 13 µSy (SD +10 µSy); hence, to detect non-inferiority between the two groups (risk of type I error 5%, risk of type II error 80%, non-inferiority limit 3 µSy) at least 138 per group are needed. The alternative hypothesis is that ld-TRA exposure is reduced compared to rightside TRA. The amount of this reduction is to be determined. An arbitrary period of 6 months should be sufficient to record the radiological exposition in at least 1000 procedures. Taking into account possible crossover between groups, a minimum proportion of 20% of procedures through distal left radial artery PCIs was mandated to guarantee adequate numerosity of the group. Kolmogorov-Smirnov analysis will be performed to evaluate the distribution of each variable analyzed. Categorical variables will be analyzed using chi-square test, and continuous variables will be analyzed using analysis of variance for normally distributed variables and Kruskal-Wallis test for variables with distribution that were not normal. If needed, log-transformation of non-normal variables will be performed. Hierarchical linear regression will be used to identify independent predictors of radiation exposure, entering control variables found to be significantly associated with radiation exposure on univariate analysis. Propensity score matching will be performed to minimize the risks of imbalances due to variation in the complexity of the diagnostic or therapeutic procedures within each operators. Prespecified analysis of subgroups (diagnostic coronary angiography vs PCI, expert operators vs fellows, use of adjunctive drapes, physical characteristics of operators) could be planned.
- Conditions
- Radiation Exposure
- Being tested
- vascular access for coronary procedures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
vascular access for coronary proceduresProcedure or surgery
comparison of x-rays exposition of interventional cardiologist according to vascular access used
| Study group | Role | What they receive |
|---|---|---|
| right radial access | diagnostic coronary angiography and/or PCI performed through right wrist and distal ("snuffbox") radial access Receives: Procedure: vascular access for coronary procedures | |
| left distal radial access | diagnostic coronary angiography and/or PCI performed through left distal ("snuffbox") radial access Receives: Procedure: vascular access for coronary procedures |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean operator radiation dose
mean operator radiation dose at the torax (expressed in µSy)
Measured: 1 year
Secondary outcomes (4)
patient radiation exposure
Patient effective dose: operator effective dose divided by a conversion factor of 0.20 mSv/Gy*cm2
Measured: from beginning to end of coronary procedure
mean fluoroscopy time
mean fluoroscopy time (minutes)
Measured: 1 year
mean DAP-normalized operator dose
operator radiation dose divided by DAP values
Measured: 1 year
mean operator effective dose
Operator effective dose: operator radiation exposure divided by 0.33
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2020
- Study start1 Sep 2020 (estimated)
- Primary completion1 Sep 2021 (estimated)
- Study completion1 Sep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Radiation ExposureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Azienda ULSS 3 Serenissima
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04403815
- Sponsor's protocol ID
- 1136
- Status last verified
- Jun 2020
- First submitted
- 15 May 2020
- Last updated
- 4 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determinants of Operator Radiation Exposure During Percutaneous Coronary Procedures According to Vascular Access: the RADIANT II Observational Study
- ClinicalTrials.gov ID
- NCT04403815
- Acronym / sponsor ID
- 1136
- Conditions
- Radiation Exposure
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Azienda ULSS 3 SerenissimaUniversity, hospital or other
- Study start
- 1 Sep 2020 (estimated)
- Primary completion
- 1 Sep 2021 (estimated)
- Study completion
- 1 Sep 2021 (estimated)
- First posted
- 27 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Trial's objective is to evaluate:
- if there's any difference between the operator radiation exposure during diagnostic coronary angiography and/or percutaneous coronary intervention (PCI) performed through right-side artery accesses (wrist transradial access and distal transradial access) versus left distal radial artery access ii. the relationship between operator radiation exposure and other clinical and procedural characteristics, to assess independent predictors of operator radiation exposure. Design of the study: prospective multicenter observational cohort registry (OCR).
The purpose of this OCR is to assess the radiation exposure of interventional cardiologist during a diagnostic coronary angiography and/or PCI according to vascular access used (see above). Coronary angiography and PCI will be performed according to usual practice
Detailed description
Patient population:
During 6 months, at least 1000 consecutive patients (age > 18 years) referred for diagnostic coronary angiography in up to 10 centers in Italy involving a minimum of 4 operators will be enrolled. To be qualified as expert, operators should have performed at least 250 transradial procedure/year in the previous 3 years and have performed at least 20 right and left distal radial procedures.
Demographic and medical history data of patients including age, sex, history of diabetes mellitus, hypertension, height and weight will be collected. Height and weight of operators will be also recorded. Type of angiographic system will be recorded. Procedural data as contrast medium amount, subclavian tortuosity, numbers of diagnostic and guiding catheters and numbers of cine-angiographic acquisitions (frames) will be also recorded.
Subclavian tortuosity will be classified as:
- Grade 1: tortuosity or calcification of the subclavian artery that can be crossed by a standard 0.035" nonhydrophilic wire facilitated with deep inspiration
- Grade 2: tortuosity or calcification of the subclavian artery that can be crossed with a 0.0035" hydrophilic wire and a standard diagnostic catheter
- Grade 3: tortuosity or calcification of the subclavian artery or congenital anomalies that require a 0.035" stiff wire and a standard catheter
- Grade 4: severe tortuosity and/or calcification of the subclavian artery or congenital anomalies preventing the catheter or guide to reach the aortic valve plane or engage the coronary ostia with a stiff wire Subclavian tortuosity > grade 2 will be considered as significative. Type of catheters and the number of views for angiography and PCI will be left to the discretion of the operator. Lead shields placed under the catheterization table, as well as ceiling mounted lead shields, will be used in every procedure. Procedural success is defined as completion of the procedure through the intended arterial access. Crossover, if needed, is permitted to femoral access or to contralateral arm or approach.
Arterial access protocol:
Right radial access: radial artery access will be obtained with a 20-gauge Teflonsheated needle using the Seldinger or the counter puncture technique. An introducer sheath is inserted in the radial artery according to local practice. An intra-arterial vasodilator cocktail will be administered consisting of ntroglycerin 200 mcg and verapamil 5 mg after sheath insertion. 5000 IU of unfractioned heparin will be administered intravenously after sheath insertion, and adequately adjusted in case of interventions. The introducer sheath will be removed at the end of the procedure, and a mechanical or inflatable pressure band will be applied to the access site to achieve hemostasis.
Distal radial accesses: following distal radial artery palpation, 1 of the 2 possible puncture sites (anatomic snuffbox or in the first intermetacarpal space) is chosen. In case of left-side access, the left hand is bent toward the left groin with support below the left elbow to ensure patient's comfort. The operator is positioned at the right side of the patient. To favor a shift of the distal radial artery to the surface of the fossa, the patient is asked to grasp his or her thumb under the other 4 fingers or to hold a roll of gauze, a 20 ml syringe, or the handle of a dedicated system. After disinfection and local anesthesia, the artery is punctured according to operator preference and/or experience using a micropuncture needle or a cannula-over-needle. An introducer sheath (preferably a slender introducer sheath) is inserted in the radial artery according to local practice. An intra-arterial vasodilator cocktail will be administered consisting of nitroglycerin 200 mcg and verapamil 5 mg after sheath insertion. 5000 IU of unfractioned heparin will be administered intravenously after sheath insertion, and adequately adjusted in case of interventions.
Coronary catheterization:
Angiographic systems were set according to the standard of the operators, and the field of view or fluoroscopic and cine-acquisition speed will be recorded for each procedure. The diagnostic procedures will be performed using a standard sequence of 3 projections for the right coronary artery and maximum 6 projections for the left coronary artery. Differently, the percutaneous coronary interventions will be performed according to the lesion and to the operator preference.
Vascular access as well as the sheath selection, catheter curve used, and the use of adjunctive tools will be at the discretion of the operator involved in the procedure.
In all procedures, standard operator radioprotection will be ensured using a lead apron, a thyroid lead collar, lower body x-ray curtain fixed on the angiographic table, an upper mobile leaded glass suspended from the ceiling, and leaded glasses. The use of adjunctive protective drapes to reduce operator radiation exposition ws left to the operator's discretion
Radiation measurement:
Radiation measures collected are fluoroscopy time (expressed in minutes), the AK (expressed in mGy) and the DAP (expressed in Gy*cm2). The number of acquired cineangiograms will be recorded. Fluoroscopy and cineangiography will be performed at 7.5 or 15 frames/s according to operators' preferences.
Operator radiation exposure is measured for each participating operator using 1 dedicated electronic dosimeter (PM1610B; Polimaster, Vienna, Austria) to be worn at mid-thorax level, in the breast pocket outside the lead apron, and expressed in µSy. The radiation and operator measures will be recorded at the beginning and the end of each procedure. For those patients who undergo a PCI after the diagnostic procedure, the measures of fluoroscopy time, DAP, and dose of the wearable dosimeters will be reset after the end of the diagnostic procedure and restart at the beginning of the PCI. To take into account possible differences in patient radiation dose affecting the operator exposure, the DAP-normalized operator dose will be also calculated.
The equivalent dose at the thorax will be also converted in operator effective dose dividing it by a factor of 33 according to apron thickness, 0.5 lead equivalent with a tube voltage under the table. Patient effective dose will be calculated using a conversion factor of 0.20 mSv/Gy*cm2.
Statistical Hypothesis and analysis:
the null hypothesis is that ld-TRA exposure to radiation is the same as right-side TRA (access site at the wrist and at the anatomical snuffbox of the right hand). In the previous RADIANT study right-side TRA was associated with a mean operator exposition of 13 µSy (SD +10 µSy); hence, to detect non-inferiority between the two groups (risk of type I error 5%, risk of type II error 80%, non-inferiority limit 3 µSy) at least 138 per group are needed. The alternative hypothesis is that ld-TRA exposure is reduced compared to rightside TRA. The amount of this reduction is to be determined. An arbitrary period of 6 months should be sufficient to record the radiological exposition in at least 1000 procedures. Taking into account possible crossover between groups, a minimum proportion of 20% of procedures through distal left radial artery PCIs was mandated to guarantee adequate numerosity of the group. Kolmogorov-Smirnov analysis will be performed to evaluate the distribution of each variable analyzed. Categorical variables will be analyzed using chi-square test, and continuous variables will be analyzed using analysis of variance for normally distributed variables and Kruskal-Wallis test for variables with distribution that were not normal. If needed, log-transformation of non-normal variables will be performed. Hierarchical linear regression will be used to identify independent predictors of radiation exposure, entering control variables found to be significantly associated with radiation exposure on univariate analysis. Propensity score matching will be performed to minimize the risks of imbalances due to variation in the complexity of the diagnostic or therapeutic procedures within each operators. Prespecified analysis of subgroups (diagnostic coronary angiography vs PCI, expert operators vs fellows, use of adjunctive drapes, physical characteristics of operators) could be planned.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| right radial access | – | Procedure: vascular access for coronary proceduresdiagnostic coronary angiography and/or PCI performed through right wrist and distal ("snuffbox") radial access |
| left distal radial access | – | Procedure: vascular access for coronary proceduresdiagnostic coronary angiography and/or PCI performed through left distal ("snuffbox") radial access |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- all-comers undergoing to diagnostic coronary angiography and/or PCI through transradial access
Key inclusion criteria (4 listed)
- patients admitted for coronary diagnostic angiography in the setting of valvular disease, stable angina, suspected coronary artery disease, acute coronary syndrome with or without ST segment elevation myocardial infarction who underwent diagnostic coronary angiography through right radial, right distal radial and left distal radial access.
- patients admitted for ad-Hoc PCI through any radial access
- patients age > 18 years-old
- signed informed consent
Key exclusion criteria (1 listed)
- hemodynamic instability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| vascular access for coronary procedurescomparison of x-rays exposition of interventional cardiologist according to vascular access used | Procedure or surgery | left distal radial access, right radial access |
Primary outcome
mean operator radiation dose
Time frame: 1 year
mean operator radiation dose at the torax (expressed in µSy)
4 secondary outcomes
patient radiation exposure
Time frame: from beginning to end of coronary procedure
mean fluoroscopy time
Time frame: 1 year
mean DAP-normalized operator dose
Time frame: 1 year
mean operator effective dose
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2020.
- Individual participant dataSharing planned: No
Related trials for Radiation Exposure
Not yet recruitingObservational study
Impact of Chronic MICROplastic Exposure on RADiotherapy of Head and Neck Cancer Patients: Clinical and Translational Oncology Study:
Head and Neck Cancer, Microplastic Exposure
Active, not recruiting
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
Melanoma (Skin Cancer)
RecruitingObservational study
Operator Radiation Exposure During Image-Guided Robotic-Assisted Bronchoscopy: A Multicenter Prospective Cohort Study
Operator Radiation Exposure
Recruiting
Randomized Trial of Next Generation Fluoroscopy System vs. Conventional Fluoroscopy System in Endoscopy
Radiation Exposure
RecruitingPhase 3
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Radiation Exposure, run by Azienda ULSS 3 Serenissima.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Andrea pacchioni, MD (00390415794241 ext. 4241, andreapacchioni@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean operator radiation dose (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2020.